Predict your next investment

HEALTHCARE | Biotechnology
gnubio.com

See what CB Insights has to offer

Founded Year

2009

Stage

Acquired | Acquired

Total Raised

$22.5M

About GnuBIO

GnuBIO is developing next-generation desktop DNA sequencing technology that will compartmentalize the entire DNA sequencing process, combining all of the steps required for sequencing in a single system, and providing the only fully integrated next-generation sequencing workflow. The GnuBIO sequencing technology is based on an emulsion based microfluidic technology which also provides a scalable sequencing solution that allows for interrogation of single genes, gene panels or whole genomes. The user of the GnuBIO system simply injects the patient sample into the GnuBIO cartridge, the appropriate panel is run - inclusive of gene capture, PCR, sequencing, and informatics analysis - and the results are ready within hours. The entire process is all on the chip, simplifying the complex sample preparation process and breaking the barrier of an obstacle that has prevented the widespread adoption of DNA sequencing.

GnuBIO Headquarter Location

620 Memorial Drive

Cambridge, Massachusetts, 02139,

United States

617-528-4500

Latest GnuBIO News

Bio-Rad shutters Cambridge facility

Oct 10, 2017

Dive Brief: Bio-Rad is shuttering its Digital Biology Center Cambridge, the former GnuBIO site. The aim is to combine the company's digital biology R&D into a single site at Pleasanton, California. There is likely to be a degree of restructuring, but it's not yet clear how many will move site, or be laid off. Bio-Rad did not respond to request for comment at the time of publicaiton. According to the Boston Business Journal, the move will result in loss of 92 jobs. Bio-Rad will turn its focus back to its droplet digital PCR (ddPCR) technology, which is being used worldwide. Dive Insight: Bio-Rad snagged GnuBIO and its fully integrated droplet-based DNA sequencing technology in a deal back in April 2014. The technology was designed to bring all the steps into a single, fast workflow for research and diagnostics. The GnuBIO site became Bio-Rad's Digital Biology Center Cambridge. At the time of the deal, Bio-Rad was already developing its own droplet digital PCR (ddPCR) technology, and launched its California-based Digital Biology Center in 2012 to develop research and diagnostic tools based around the technology. While the closure in Cambridge does not appear to be an abandonment of a deal that cost the company $39.7 million in cash and $10 million in contingent payments, the company is likely looking to cut costs. Its second quarter 2017 net sales were $504.7 million,  down 2.3% year-on-year, and its net income was $5.0 million, compared with $18.0 million during the same period in 2016. "The second quarter of 2017 has been one of our most challenging… These sales results, along with substantial spending related to implementing new systems and operations in Europe, as well as increased expenditures for newly acquired products and technology, combined to produce a disappointing operating result for the quarter," said Norman Schwartz, Bio-Rad president and CEO during a second quarter earnings presentation. Follow Suzanne Elvidge on Twitter

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GnuBIO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GnuBIO is included in 1 Expert Collection, including Omics.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

GnuBIO Patents

GnuBIO has filed 17 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/16/2016

12/31/2019

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/16/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/31/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.